Epstein-Barr virus and telomerase

From cell immortalization to therapy

Riccardo Dolcetti, Silvia Giunco, Jessica Dal Col, Andrea Celeghin, Katy Mastorci, Anita De Rossi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Overcoming cellular senescence is strictly required for virus-driven tumors, including those associated with Epstein-Barr virus (EBV). This critical step is successfully accomplished by EBV through TERT expression and telomerase activation in infected cells. We herein review the complex interplay between EBV and TERT/telomerase in EBV-driven tumorigenesis. Evidence accumulated so far clearly indicates that elucidation of this issue may offer promising opportunities for the design of innovative treatment modalities for EBV-associated malignancies. Indeed, several therapeutic strategies for telomerase inhibition have been developed and are being investigated in clinical trials. In this respect, our recent finding that TERT inhibition sensitizes EBV+ lymphoma cells to antivirals through activation of EBV lytic replication is particularly promising and provides a rationale for the activation of clinical studies aimed at assessing the effects of combination therapies with TERT inhibitors and antivirals for the treatment of EBV-associated malignancies.

Original languageEnglish
Article number8
JournalInfectious Agents and Cancer
Volume9
Issue number1
DOIs
Publication statusPublished - Feb 26 2014

Fingerprint

Telomerase
Human Herpesvirus 4
Therapeutics
Antiviral Agents
Oncogenic Viruses
Cell Aging
Virus Replication
Lymphoma
Neoplasms
Carcinogenesis
Clinical Trials

Keywords

  • Antivirals
  • Cancer
  • Epstein-Barr virus
  • Lymphoma
  • Lytic replication
  • Telomerase

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology
  • Epidemiology
  • Cancer Research

Cite this

Epstein-Barr virus and telomerase : From cell immortalization to therapy. / Dolcetti, Riccardo; Giunco, Silvia; Dal Col, Jessica; Celeghin, Andrea; Mastorci, Katy; De Rossi, Anita.

In: Infectious Agents and Cancer, Vol. 9, No. 1, 8, 26.02.2014.

Research output: Contribution to journalArticle

@article{704d33b725694005a49e7ff772697444,
title = "Epstein-Barr virus and telomerase: From cell immortalization to therapy",
abstract = "Overcoming cellular senescence is strictly required for virus-driven tumors, including those associated with Epstein-Barr virus (EBV). This critical step is successfully accomplished by EBV through TERT expression and telomerase activation in infected cells. We herein review the complex interplay between EBV and TERT/telomerase in EBV-driven tumorigenesis. Evidence accumulated so far clearly indicates that elucidation of this issue may offer promising opportunities for the design of innovative treatment modalities for EBV-associated malignancies. Indeed, several therapeutic strategies for telomerase inhibition have been developed and are being investigated in clinical trials. In this respect, our recent finding that TERT inhibition sensitizes EBV+ lymphoma cells to antivirals through activation of EBV lytic replication is particularly promising and provides a rationale for the activation of clinical studies aimed at assessing the effects of combination therapies with TERT inhibitors and antivirals for the treatment of EBV-associated malignancies.",
keywords = "Antivirals, Cancer, Epstein-Barr virus, Lymphoma, Lytic replication, Telomerase",
author = "Riccardo Dolcetti and Silvia Giunco and {Dal Col}, Jessica and Andrea Celeghin and Katy Mastorci and {De Rossi}, Anita",
year = "2014",
month = "2",
day = "26",
doi = "10.1186/1750-9378-9-8",
language = "English",
volume = "9",
journal = "Infectious Agents and Cancer",
issn = "1750-9378",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Epstein-Barr virus and telomerase

T2 - From cell immortalization to therapy

AU - Dolcetti, Riccardo

AU - Giunco, Silvia

AU - Dal Col, Jessica

AU - Celeghin, Andrea

AU - Mastorci, Katy

AU - De Rossi, Anita

PY - 2014/2/26

Y1 - 2014/2/26

N2 - Overcoming cellular senescence is strictly required for virus-driven tumors, including those associated with Epstein-Barr virus (EBV). This critical step is successfully accomplished by EBV through TERT expression and telomerase activation in infected cells. We herein review the complex interplay between EBV and TERT/telomerase in EBV-driven tumorigenesis. Evidence accumulated so far clearly indicates that elucidation of this issue may offer promising opportunities for the design of innovative treatment modalities for EBV-associated malignancies. Indeed, several therapeutic strategies for telomerase inhibition have been developed and are being investigated in clinical trials. In this respect, our recent finding that TERT inhibition sensitizes EBV+ lymphoma cells to antivirals through activation of EBV lytic replication is particularly promising and provides a rationale for the activation of clinical studies aimed at assessing the effects of combination therapies with TERT inhibitors and antivirals for the treatment of EBV-associated malignancies.

AB - Overcoming cellular senescence is strictly required for virus-driven tumors, including those associated with Epstein-Barr virus (EBV). This critical step is successfully accomplished by EBV through TERT expression and telomerase activation in infected cells. We herein review the complex interplay between EBV and TERT/telomerase in EBV-driven tumorigenesis. Evidence accumulated so far clearly indicates that elucidation of this issue may offer promising opportunities for the design of innovative treatment modalities for EBV-associated malignancies. Indeed, several therapeutic strategies for telomerase inhibition have been developed and are being investigated in clinical trials. In this respect, our recent finding that TERT inhibition sensitizes EBV+ lymphoma cells to antivirals through activation of EBV lytic replication is particularly promising and provides a rationale for the activation of clinical studies aimed at assessing the effects of combination therapies with TERT inhibitors and antivirals for the treatment of EBV-associated malignancies.

KW - Antivirals

KW - Cancer

KW - Epstein-Barr virus

KW - Lymphoma

KW - Lytic replication

KW - Telomerase

UR - http://www.scopus.com/inward/record.url?scp=84895927754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895927754&partnerID=8YFLogxK

U2 - 10.1186/1750-9378-9-8

DO - 10.1186/1750-9378-9-8

M3 - Article

VL - 9

JO - Infectious Agents and Cancer

JF - Infectious Agents and Cancer

SN - 1750-9378

IS - 1

M1 - 8

ER -